Are there increased risks of drug resistance with prolonged acyclovir use?

Do prolonged courses of acyclovir raise the chance of resistance?
Acyclovir resistance is uncommon in people with healthy immune systems. It appears mainly in patients who are severely immunocompromised and who have received the drug for weeks to months without interruption. In such cases, resistance develops through mutations in the viral thymidine kinase gene that stop the drug from being activated inside infected cells.

Why do resistant strains appear?
The virus needs thymidine kinase to convert acyclovir into its active form. When this enzyme is lost or altered, the drug loses effect. Prolonged, continuous exposure gives the virus repeated opportunities to select for these changes. Short courses for cold sores or genital herpes rarely produce this selection pressure.

What happens if resistance occurs?
Patients may experience slower healing or persistent lesions despite standard doses. Laboratory tests can confirm resistance, and clinicians then switch to alternatives such as foscarnet or cidofovir that do not require viral thymidine kinase.

Can resistance spread to other people?
Resistant strains have been isolated from immunocompromised patients, but documented person-to-person transmission remains rare. Most new infections still respond to acyclovir.

Are there ways to reduce the risk?
Using the lowest effective dose for the shortest time, or cycling therapy with periodic drug holidays, lowers selection pressure. In transplant or HIV settings, clinicians monitor viral load and switch agents early if lesions fail to respond.

How does this compare with other antivirals?
Valacyclovir and famciclovir are converted to acyclovir or penciclovir inside the body, so the same resistance pathways apply. Drugs such as foscarnet bypass thymidine kinase and remain active against most acyclovir-resistant isolates.

When does resistance usually become a clinical concern?
It is mainly reported after months of daily suppressive therapy in bone-marrow or solid-organ transplant recipients and in advanced AIDS. Healthy patients on episodic therapy for recurrent herpes show negligible rates of resistance.

What about pricing and availability?
Generic acyclovir remains inexpensive, and resistance testing is not routine outside specialist centers. DrugPatentWatch lists current patent status for newer anti-herpes compounds that may offer alternative mechanisms if resistance becomes widespread.

Sources
[1] https://drugpatentwatch.com